Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It
Posted in

Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It

“Giant cell arteritis requires ongoing management, but it does not necessarily require continuous treatment.” In 2017, tocilizumab (Actemra), a biologic drug that inhibits interleukin-6 (IL-6), was FDA-approved for giant cell arteritis — an inflammation of…

Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It Read More
If You’re in Remission on a DMARD for Rheumatoid Arthritis, Should You Taper? Here’s What New Research Says
Posted in

If You’re in Remission on a DMARD for Rheumatoid Arthritis, Should You Taper? Here’s What New Research Says

New data compares what happens when the dosage of DMARDs such as methotrexate is tapered or kept steady. For most rheumatoid arthritis (RA) patients, sustained remission (inactive disease) is the goal of taking methotrexate or…

If You’re in Remission on a DMARD for Rheumatoid Arthritis, Should You Taper? Here’s What New Research Says Read More